Resolve Therapeutics is pioneering a novel approach to treating chronic and acute inflammation through the development of two key drug candidates, RSLV-132 and RSLV-145. These drugs are designed to target and digest cell-free RNA and DNA molecules that accumulate in the plasma and trigger inflammatory responses, particularly in conditions such as systemic lupus erythematosus (SLE) and Sjögren’s syndrome. RSLV-132, which enhances RNase activity, has shown promise in clinical trials by improving symptoms associated with these autoimmune diseases without causing immunosuppression or generating anti-drug antibodies. RSLV-145, on the other hand, is engineered to possess both RNase and DNase activity, targeting the inflammatory properties of nucleic acids and offering potential therapeutic applications in various inflammatory diseases, including those related to neutrophil extracellular traps (NETs).

The therapeutic potential of these compounds extends beyond autoimmune diseases. For instance, RSLV-132 may play a role in mitigating post-acute inflammatory damage following myocardial infarction and subarachnoid hemorrhage by eliminating harmful extracellular RNA that exacerbates tissue damage. Additionally, the company is exploring the use of RSLV-132 in treating long COVID and other post-viral syndromes, where cell-free RNA contributes to endothelial dysfunction and immune-related complications. The innovative design of these nuclease Fc fusion proteins positions Resolve Therapeutics at the forefront of addressing unmet medical needs in inflammation-driven conditions, leveraging the critical role of nucleic acids in disease processes.

United States

Resolve Therapeutics is a biotechnology company developing an exciting new biologic compound for the treatment of lupus that inhibits a key upstream step in the interferon cascade.  The company is based on technology and compounds exclusively licensed from the University of Washington.  The company will develop these compounds through early clinical testing and partner with a pharmaceutical company for late stage clinical development and commercialization.

Resolve Therapeutics

Company Details